PURPOSE: The aim of this study was to determine the effect of a longer interval between neoadjuvant chemoradiation and surgery on perioperative morbidity and oncologic outcomes. METHODS: A colorectal cancer database was queried for clinical stage II and III rectal cancer patients undergoing neoadjuvant chemoradiation followed by proctectomy between 1997 and 2007. The neoadjuvant regimen consisted of long course external beam radiation and 5-fluorouracil chemotherapy. Patients with inflammatory bowel disease, hereditary cancer, extracolonic malignancy, urgent surgery, or non-validated treatment dates were excluded. Patients were divided into two groups according to the interval between chemoradiation and surgery (<8 and ≥ 8 weeks). Perioperative complications and oncologic outcomes were compared. RESULTS: One hundred seventy-seven patients were included. Groups were comparable with respect to demographics, tumor, and treatment characteristics. Perioperative complications were not affected by the interval between chemoradiation and surgery. Patients undergoing surgery ≥ 8 weeks after chemoradiation experienced a significant improvement in pathologic complete response rate (30.8% vs. 16.5%, p = 0.03) and had decreased 3-year local recurrence rate (1.2% vs. 10.5%, p = 0.04). A Cox regression analysis was performed to assess the compounding effect of a complete pathologic response on oncologic outcome. A longer interval correlated with less local recurrence, although statistical significance was not reached (p = 0.07). CONCLUSION: An interval between chemoradiation and surgery ≥ 8 weeks is safe and is associated with a higher rate of pathologic complete response and decreased local recurrence.
PURPOSE: The aim of this study was to determine the effect of a longer interval between neoadjuvant chemoradiation and surgery on perioperative morbidity and oncologic outcomes. METHODS: A colorectal cancer database was queried for clinical stage II and III rectal cancerpatients undergoing neoadjuvant chemoradiation followed by proctectomy between 1997 and 2007. The neoadjuvant regimen consisted of long course external beam radiation and 5-fluorouracil chemotherapy. Patients with inflammatory bowel disease, hereditary cancer, extracolonic malignancy, urgent surgery, or non-validated treatment dates were excluded. Patients were divided into two groups according to the interval between chemoradiation and surgery (<8 and ≥ 8 weeks). Perioperative complications and oncologic outcomes were compared. RESULTS: One hundred seventy-seven patients were included. Groups were comparable with respect to demographics, tumor, and treatment characteristics. Perioperative complications were not affected by the interval between chemoradiation and surgery. Patients undergoing surgery ≥ 8 weeks after chemoradiation experienced a significant improvement in pathologic complete response rate (30.8% vs. 16.5%, p = 0.03) and had decreased 3-year local recurrence rate (1.2% vs. 10.5%, p = 0.04). A Cox regression analysis was performed to assess the compounding effect of a complete pathologic response on oncologic outcome. A longer interval correlated with less local recurrence, although statistical significance was not reached (p = 0.07). CONCLUSION: An interval between chemoradiation and surgery ≥ 8 weeks is safe and is associated with a higher rate of pathologic complete response and decreased local recurrence.
Authors: David E Stein; Najjia N Mahmoud; Pramila Rani Anné; Deborah G Rose; Gerald A Isenberg; Scott D Goldstein; Edith Mitchell; Robert D Fry Journal: Dis Colon Rectum Date: 2003-04 Impact factor: 4.585
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Marlies S Reimers; Charla C Engels; Peter J K Kuppen; Cornelis J H van de Velde; Gerrit J Liefers Journal: Nat Rev Clin Oncol Date: 2014-06-24 Impact factor: 66.675
Authors: Fabian A Holman; Michael G Haddock; Leonard L Gunderson; Miranda Kusters; Grard A P Nieuwenhuijzen; Hetty A van den Berg; Heidi Nelson; Harm J T Rutten Journal: J Gastrointest Oncol Date: 2016-12
Authors: Felipe A Calvo; Virginia Morillo; Marcos Santos; Javier Serrano; Marina Gomez-Espí; Marcos Rodriguez; Emilio Del Vale; Jose Luis Gracia-Sabrido; Carlos Ferrer; Claudio Sole Journal: J Cancer Res Clin Oncol Date: 2014-06-01 Impact factor: 4.553
Authors: Daniel Delitto; Thomas J George; Tyler J Loftus; Peihua Qiu; George J Chang; Carmen J Allegra; William A Hall; Steven J Hughes; Sanda A Tan; Christiana M Shaw; Atif Iqbal Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: Annefleur E M Berkel; Dankert P Woutersen; Job van der Palen; Joost M Klaase Journal: J Gastrointest Surg Date: 2014-06-18 Impact factor: 3.452